Product Information
GRISEOFULVIN 125 MG/5 ML SUSP is a generic product labeled by Cipla USA Inc., priced at $0.2521 per ML under NDC 69097036108. Its NADAC has been published 473 times since May 17, 2017.
FDA first approved this application on Sep 10, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
125 mg/5mL
Manufacturer
Cipla USA Inc.NDC
69097036108
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
GRISEOFULVINApproval Type
Generic (ANDA)
FDA Application
ANDA065354FDA Approved
9/10/2007
TE Code
AB
On Market Since
3/6/2017
Pharmacological Classes
Price Statistics
The NADAC for GRISEOFULVIN 125 MG/5 ML SUSP has been published 473 times since May 17, 2017, and over the history we have for it it has risen 30.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2521 per ML |
|---|---|
| All-time high | $0.4099 (Dec 13, 2023) |
| All-time low | $0.1508 (Jun 21, 2017) |
| 52-week high | $0.2898 |
| 52-week low | $0.2471 |
| Median price | $0.2556 |
| Average price | $0.2782 |
| Largest weekly change | +28.2% (Jul 19, 2017) |
| Weeks tracked | 473 |
| Tracking since | May 17, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the grisofulvin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Cipla USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
grisofulvin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tubulin Inhibiting Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GRISEOFULVIN 125 MG/5 ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for GRISEOFULVIN 125 MG/5 ML SUSP, manufactured by Cipla USA Inc., is $0.2521 per ML (NDC 69097036108), effective Sep 30, 2026.
How has the price of GRISEOFULVIN 125 MG/5 ML SUSP changed over time?
Over the history we have for it, the NADAC for GRISEOFULVIN 125 MG/5 ML SUSP has risen 30.8%. It has been tracked across 473 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for GRISEOFULVIN 125 MG/5 ML SUSP?
Since May 17, 2017, the NADAC for GRISEOFULVIN 125 MG/5 ML SUSP has ranged from a low of $0.1508 (Jun 21, 2017) to a high of $0.4099 (Dec 13, 2023), with a median of $0.2556 per ML.
Are there cheaper alternatives to GRISEOFULVIN 125 MG/5 ML SUSP?
No other NADAC-published product currently shares the active ingredient and strength of GRISEOFULVIN 125 MG/5 ML SUSP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GRISEOFULVIN 125 MG/5 ML SUSP?
GRISEOFULVIN 125 MG/5 ML SUSP (NDC 69097036108) is labeled by Cipla USA Inc., and CMS classifies it as a generic product.